Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT04385589
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT04385589
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT04385589. Randomized; double masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2020-12-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
- Condition
- Heart Failure
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- insulin
- Lead sponsor
- Assiut University
Record details
- Record id
cardio:ct-nct04385589- Content hash
ba59aa45bbedee8302de47b4b86263feee944f9bd132bfd89b7739828df5c48d